group showed disappointment of IRI change. In selective group, the serum TNF-a and HMGB-1 level was lower than systemic group (TNF-a: 30.6 vs 85.4 pg/ml, p<0.05, HMGB-1: 2.6 vs 11.4 ng/ml, p<0.05). The mRNA expression of IL-1b was also suppressed in selective group specimen.
INTRODUCTION AND OBJECTIVES: It was reported that some variables were revealed remain renal function after live donor nephrectomy. This study was conducted to determine the influence of visceral and subcutaneous adipose tissue on renal function in living kidney donors.
METHODS: Between July 2013 and February 2015, a total of 75 kidney donors who underwent living donor nephrectomy at our institution were analyzed. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were measured at the level of the umbilicus using CT scan. The border of the intra-abdominal cavity was outlined on the CT image, the cross-sectional surface areas of the visceral fat and subcutaneous fat were calculated by a single urologist using Xelis CT software (INFINITT, Seoul, Korea) (Fig 1.) . Renal function was estimated with the Modification of Diet in Renal Disease formula till six months after kidney donation. The relationship between preoperative visceral and subcutaneous adipose tissue and recovery of renal function was analyzed.
RESULTS: Thirty-three donors (44%) were male, and 13 (17.3%) grafts were secured from the right side. The mean BMI was 23.5AE2.6 kg/m2 and the mean preoperative eGFR was 103.0AE19.6 mL/ min/1.73 m2. The mean VAT was 73.0AE41.6cm3; SAT was 117.5AE70.2cm3, and VAT/SAT ratio was 0.7AE0.5. On multivariate linear regression, preoperative eGFR, ?eGFR, and VAT/SAT ratio were independently associated with eGFR at 6th month (Table 2) . A ROC curve analysis showed that preoperative eGFR, ?eGFR and VAT/SAT ratio were highly predictive of developing of CKDIII at 6th month after donor nephrectomy (AUC ¼ 0.933, p < 0.001).
CONCLUSIONS: Pre-donation eGFR, ?eGFR and V/S ratio are associated with the development of delayed renal recovery (GFR <60 ml/min/1.72m2) 6th month after donation. VAT/SAT ratio was associated with the postoperative renal function in living kidney donors. Kidney donors with higher VAT/SAT ratio require close observation, given their predisposition to CKD III after donation METHODS: The effects of CORM-3 (200 mM) were compared in normal kidney epithelial cells (HK-2, LLC-PK1) and renal cancer cells (Caki1, Caki2), which were treated with CP (50~200 mM) and induced IRI. To induce IRI condition, cell plates were placed anaerobic chamber (37 C, 95% N2, 5% CO2) for 48hrs, and then cell medium was changed complete medium and incubation in 37 C humidified CO2 incubator for 6hr. The effect of CORM-3 on stimulated IRI and CP treated normal cells/RCC was the determined by measuring the cell viability (CCK assay), TNF-a mRNA induction (Q-RT PCR), protein expression of cleaved caspase 3 and oxidative stress markers including Erk1/2, JNK, P38 (western blot).
RESULTS: Viability after IRI were approximately 40% compared with control. Protective effect of CORM-3 on IRI in vitro model was dose-dependent. Cell viability was 40% recovered in 200 mM CORM-3 pretreated cells compared with control cells. Confluent normal cells and cancer cells were exposed for 24h to CP (50~200 mM) alone or in combined with CORM-3 (12.5~200 mM). Protective effects of CORM-3 on CP-treated cells were weaker than those of IRI model. TNF-a mRNA induction occurs following stimulate IRI or CP exposed cells and expression of TNF-a mRNA levels decreased in CORM-3 pretreated cells. Also, IRI or CP-induced activated oxidative stress markers decreased in CORM-3 pretreated cells. CORM-3 reduced expression of c-caspase-3 which is an apoptotic marker.
CONCLUSIONS: Our data demonstrate that protective effect of CORM-3 on CP-treated and IRI model in vitro. We suggest that CO attenuates IRI and CP induced cytotoxicity by amelioration of inflammatory and oxidative stress pathways. These effects were observed in not only normal kidney cells but also renal cancer cells.
INTRODUCTION AND OBJECTIVES:
Prostate cancer (PC) in renal transplant recipients (RTR) has not been widely studied and its incidence remains controversial, reported 2-5 times more than general population. The management of this disease is challenging because it is believed that RTR under immunosuppressive therapy may have increased postoperative morbidity and higher rate of tumor progression. Currently there are not guidelines or consensus about the management of this condition. The aim of the study was to analyze our experience in the management of PC in RTR.
METHODS: Prospective and consecutive study in a single tertiary centre from 2003-2015. Inclusion of RTR diagnosed of PC by urinary symptoms, prostatic specific antigen (PSA), digital rectal examination, imaging and biopsies. PC assessment for staging and treatment was in agreement with the contemporary guidelines for the general population. Main outcome measures included demographics, characteristics and associated factors, type of treatment, complications, oncological outcomes and follow-up. Retrospective and descriptive analysis.
RESULTS: During the study period 1330 renal transplants were performed, diagnosed of PC in 28 RTR (2.1%), mean age 66 yearsAE6.6 (51-78). Type of donors were cadaveric (n¼26) and live (n¼2). Immunosuppressive therapy: without mTOR (n¼14) and with mTOR (n¼14). Mean time between renal transplantation and PC diagnosis 111 monthsAE75 (24-270). Median PSA of 9.6ng/ml and PSA ratio 0.19. Treatment: a) Radical prostatectomy (n¼20): perineal approach (n¼16), laparoscopic (n¼2), robotics (n¼2)/ lymphadenectomy was performed in one patient; b) Radiotherapy combined with hormone therapy (n¼6); c) Active surveillance (n¼2). Histology: pT2 (n¼15), pT3a (n¼4) and !pT3b (n¼1). No graft loss due to PC treatment was reported. Complications (18%): incontinence post-prostatectomy (n¼2), anastomotic stricture (n¼2) and urinary fistula (n¼1). Outcomes: Remission of the 85% (n¼22), Biochemical recurrence after radical prostatectomy treated with salvage radiotherapy (n¼4). Mortality by other causes without evidence of recurrence (n¼11), loss of monitoring (n¼1). Not specific mortality from cancer prostate was reported. Observed survival rates were 100% at 12 months after treatment. Mean follow-up was 61 monthsAE37 .
CONCLUSIONS: This is the first largest series to analyze the management of PC in RTR from a single center in Spain. PC after renal transplantation could be managed as any non-organ transplant patient with the same range of therapeutic options. According to our experience, these patients has similar histopathologic evaluation, posttreatment complications, rate of remission and recurrence than non-transplant patients, without specific mortality from PC. Active surveillance should also be provided in RTR despite being under immunosuppressive treatment.
Source of Funding: none

MP06-17 UROTHELIAL CARCINOMA AFTER KIDNEY TRANSPLANT: A HETEROGENEUS ENTITY IN TERMS OF DIAGNOSIS, TREATMENTS AND ONCOLOGICAL OUTCOMES
Vital Hevia*, Javier Lorca, Victoria Gomez, Sara Alvarez, Victor Diez, Francisco Javier Burgos, Madrid, Spain INTRODUCTION AND OBJECTIVES: Cancer development after KT is increasing, and urothelial carcinoma (UCa) incidence has been estimated 3 times higher, especially focused in bladder. However, upper urinary tract (UUT) can also be affected, both in native and less commonly in graft UUT. Management of UCa after KT is demanding because of aggressiveness and potential graft involvement. The aim of the study is to assess all UCa developed after KT, as well as treatments performed and oncological outcomes METHODS: Retrospective analysis of 1.693 KT at our institution between 1977-October 2016. Age, sex, tumor location, TNM stage, tumor grade, presence of Cis, treatments and oncological outcomes are assessed, including median Overall Survival (mOS) and cancer-specificsurvival (CSS) RESULTS: 13 patients developed 14 UCa (0.83%), 61.5% male. Median age at the moment of cancer was 62.5 years (range 40-81) and median time from KT to cancer 52.5 months (range 2-209). UCa were located in bladder (8), in native UUT (1) and in graft UUT (5). At diagnosis, only 1 patient was metastatic and 35% of the cases (5/14) had Cis associated. Regarding tumor grade, 1 was G2, 9 were G3 and 4 were G4. Pathologic stage and treatments performed for UCa after KT are detailed in Table 1 . 67% patients with non-muscle-invasive bladder tumor (NMIBT) received BCG. All patients with graft UUT UCa had locally advanced tumors and were treated with graft RNU and pelvic lymphadenectomy, returning to dialysis. At present, 69.2% (9/13) are alive, and median-overall-survival (mOS) is 36 months (range 2-182). Of the total 4 deaths, 1 was cancer-related, 1 during RC postoperative course and the other 2 ESRD-related. Cancer-specific-survival (CSS) was 92% (12/13).
CONCLUSIONS: Bladder is the most common place of UCa after KT. BCG is also a part of the treatment in these patients. Graft UUT UCa was relatively high in our study comparing to literature. It is usually locally advanced and sometimes unresectable. mOS of UCa after KT is 36 months, which is lower than other uro-cancers in this population. Treatment of this cancer is challenging and can potentially involve the graft, being necessary to remove it and so returning to dialysis Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e79
